ANRO · Alto Neuroscience, Inc. · Executive Compensation
$23.72
-0.29 (-1.21%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$1.06B
Shares
39.24M
Volume · Oct 6
389.38K
Avg daily vol (3M)
551.83K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Amit Etkin | M.D., Ph.D. President, Chief Executive Officer, and Chair of the Board | $2,188,487 |
| Nicholas Smith | Chief Financial Officer and Chief Business Officer | $1,541,585 |
| Michael Hanley | Chief Operating Officer | $1,212,928 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Amit Etkin | M.D., Ph.D. President, Chief Executive Officer, and Chair of the Board | $4,065,848 |
| Michael Hanley | Chief Operating Officer | $2,442,628 |
| Nicholas Smith | Chief Financial Officer and Chief Business Officer | $1,995,964 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Nicholas C. Smith | President and Chief Financial Officer | Appointed | 2026-08-27 |
| Andrew Miller, Ph.D. | member of the Board | Appointed | 2026-05-28 |
| Christopher Nixon Cox | Class III director | Appointed | 2025-08-13 |
| Christopher Nixon Cox | Class II director | Resigned | 2025-08-13 |
| Andrew Dreyfus | Class I director | Appointed | 2025-08-13 |
| Andrew Dreyfus | Class III director | Resigned | 2025-08-13 |
| Ramiro (Raymond) Sanchez, M.D. | member of the Board (Class II director) and member of the NCGC | Appointed | 2025-08-13 |
| Michael Hanley | Chief Operating Officer | Appointed | 2024-05-21 |
| Maha Radhakrishnan, M.D. | member of the Board and as a member of the NCGC | Appointed | 2024-03-11 |